Cephea Valve

Cephea Valve Technologies is a medical device company focused on the development of a transcatheter mitral valve replacement (TMVR) system. The company's technology is designed to treat patients with mitral regurgitation through a minimally invasive, catheter-based approach, providing an alternative to traditional open-heart surgery. The Cephea valve is specifically engineered to accommodate the complex anatomy of the mitral valve and ensure a secure, leak-free fit. In January 2019, the company was acquired by Abbott, a global leader in structural heart therapies, to bolster its portfolio of minimally invasive heart valve solutions. The system is currently undergoing clinical evaluation in early feasibility studies to establish its safety and performance.